Skip to main content
Bioversys N logo

Bioversys N — Investor Relations & Filings

Ticker · BIOV ISIN · CH0210362643 LEI · 894500UFIGC75NPZEZ68 SW Manufacturing
Open in API
Filings indexed 78 across all filing types
Latest filing 2026-03-31 Regulatory Filings
Country CH Switzerland
Listing SW BIOV

About Bioversys N

https://www.bioversys.com/

Bioversys is a clinical-stage biopharmaceutical company focused on the research and development of novel antibacterial therapies to combat the global threat of antimicrobial resistance (AMR). The company develops small molecule drugs that act on novel bacterial targets through innovative modes of action. Its clinical pipeline includes BV100, a treatment for serious hospital infections caused by Acinetobacter baumannii, and Alpibectir, a novel potentiator for multidrug-resistant tuberculosis (MDR-TB). Both candidates are in Phase 2 clinical development. The company's earlier-stage portfolio includes BV200, an anti-virulence compound for Staphylococcus aureus infections, and BV500 for Nontuberculous mycobacteria (NTM) infections, addressing critical unmet medical needs.

Recent filings

Filing Released Lang Actions
BioVersys strengthens Ansamycin platform and NTM research through collaboration and license agreement with Hackensack Meridian Health
Regulatory Filings Classification · 1% confidence The document is a corporate press release announcing an exclusive collaboration and license agreement between BioVersys AG and Hackensack Meridian Health, describing the scientific partnership and upfront/royalty payments. It is not a financial report (10-K, IR), not a management or governance document, not a transaction in shares or M&A takeover, and not an earnings or dividend notice. It is a general regulatory/corporate announcement of a business deal, which falls under the fallback category Regulatory Filings (RNS).
2026-03-31 English
BioVersys strengthens Ansamycin platform and NTM research through collaboration and license agreement with Hackensack Meridian Health
Regulatory Filings Classification · 1% confidence The document is a corporate press release by BioVersys AG announcing an exclusive collaboration and license agreement with Hackensack Meridian Health to advance its Ansamycin Chemistry platform. It contains no financial results, no board changes, no fundraising or merger details, and is not a presentation, transcript, or report on ESG. It is a general regulatory news announcement of a corporate partnership, which best fits the fallback category “Regulatory Filings” (RNS).
2026-03-31 English
BioVersys Reports Corporate Highlights and Financial Results for the Full Year 2025
Earnings Release Classification · 1% confidence The document is an 'ad hoc announcement' from BioVersys AG regarding its full-year 2025 financial results. It provides a summary of corporate highlights, pipeline progress, and key financial figures (income, loss, cash position). Crucially, the text explicitly states that it is an announcement of the results and mentions that the 'Annual Report 2025' is available separately on their website. Following the 'Menu vs Meal' rule, since this is a summary announcement of the report rather than the full 10-K/Annual Report document itself, it is classified as an Earnings Release (ER). FY 2025
2026-03-18 English
BioVersys Reports Corporate Highlights and Financial Results for the Full Year 2025
Earnings Release Classification · 1% confidence The document is an 'ad hoc announcement' regarding the release of the company's full-year 2025 financial results. It provides a summary of key highlights, financial figures, and pipeline updates, and explicitly states that the full Annual Report 2025 is available on the company's website. Because the document is an announcement of the report rather than the full report itself, and it serves as the initial release of financial results, it is classified as an Earnings Release (ER). FY 2025
2026-03-18 English
BioVersys Annual Report 2025
Annual Report Classification · 1% confidence The document is titled 'ANNUAL REPORT 2025' and contains comprehensive sections including a Chairman and CEO's letter, portfolio and pipeline updates, corporate governance, compensation reports, and full consolidated financial statements (IFRS). It covers the company's performance, financial results, and strategic outlook for the fiscal year 2025. It is clearly the primary annual reporting document for BioVersys. FY 2025
2026-03-18 English
BioVersys Receives Green Light from US FDA for BV100 HABP/VABP Phase 3 Pivotal Trial Start
Regulatory Filings Classification · 1% confidence The document is an 'ad hoc' announcement from BioVersys AG regarding regulatory approval from the US FDA to proceed with a Phase 3 clinical trial for their drug candidate BV100. It is a corporate news release detailing clinical trial progress, regulatory milestones, and forward-looking statements. It does not fit into specific financial reporting categories like 10-K, IR, or ER, nor is it a simple report publication announcement. Therefore, it is classified as a general regulatory announcement (RNS).
2026-03-16 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.